Overexpression of eIF4E gene in acute myeloid leukemia and its relation with disease progression

The aim of this study was to detect the expression level of eIF4E gene in patients with non-treated,remission and non-remission/relapse acute myeloid leukemia(AML),and other non-malignant haematologic diseases so as to analyze and reveal the relationship of eIF4E gene expression with AML progression.SYBR Green I RT-PCR was used to assay the expression level of eIF4E mRNA extracted from bone marrow mononuclear cells in 30 patients with AML(6 in M2,5 in M3,8 in M4,10 in M5,1 in M6) and 20 patients with non-malignant hematologic diseases.The β2-microglubin(β2M) was used as internal reference and the formula 2-△Ct×100% was applied to calculate the expression level of eIF4E gene.The results showed that the eIF4E expression level(7.098±5.544)% in patients with non-treated and non-remitted/relapsed AML was significantly higher than that in patients with remission(0.964±0.312)%(P0.01) and non-malignant hematologic diseases(0.248±0.163)%(P0.01).There was no difference between latter two group patients,even though the expression level of eIF4E gene in patients with M4 and M5 was higher.As compared with non-malignant hematologic diseases,the expression level of eIF4E gene of patients with remission patients showed no significant difference.It is concluded that the over-expression of eIF4E gene has been found in patients with AML,and its level obviously decreases along with remission of disease,thus the eIF4E gene may be a surveillance parameter for disease progression.